Erik Arneson, MD
Neurology · Des Moines, IANPI 1194382119
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,314 of the $9,743 with a category attached, or 64.8%. 18 manufacturers reported payments, led by Sanofi at 31.2% of the total. 2025 is the largest year on record at $8,490, more than ten times the $100 reported in 2023.
Across 81 payments — averaging $120.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Genentech USA, Inc.$2K
- TG Therapeutics, Inc.$2K
- EMD Serono, Inc.$902
- Biogen$555
- Bristol Myers Squibb$157
- plus $667 from 12 others
What the payments were for
- Consulting fees$6,31465%
- Food & beverage$3,42935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 3 | $3,041 |
| Genentech USA, Inc. | 5 | $2,497 |
| TG Therapeutics, Inc. | 26 | $1,923 |
| EMD Serono, Inc. | 9 | $902 |
| Biogen | 18 | $555 |
| Bristol Myers Squibb | 4 | $157 |
| Roche Products Limited | 1 | $126 |
| Vanda Pharmaceuticals Inc. | 1 | $105 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Amgen | 1 | $90 |
| Pfizer | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $33 |
| CSL Behring | 1 | $32 |
| Argenx US, Inc. | 1 | $31 |
| AstraZeneca | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,743 in reported general payments places this provider in the 85th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 20 | $4,197 |
| Levetiracetam | 28 | $883 |
| Gabapentin | 30 | $467 |
Paid to pharmacies, not to this prescriber.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
- Irving WolfeDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.